Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ('METRIC'): a randomized multicenter study

Autor: Linda T. Vahdat, Peter Schmid, Andres Forero-Torres, Kimberly Blackwell, Melinda L. Telli, Michelle Melisko, Volker Möbus, Javier Cortes, Alberto J. Montero, Cynthia Ma, Rita Nanda, Gail S. Wright, Yi He, Thomas Hawthorne, Rebecca G. Bagley, Abdel-Baset Halim, Christopher D. Turner, Denise A. Yardley

Publikováno v: npj Breast Cancer, Vol 7, Iss 1, Pp 1-10 (2021)

Abstract The METRIC study (NCT#0199733) explored a novel antibody–drug conjugate, glembatumumab vedotin (GV), targeting gpNMB that is overexpressed in ~40% of patients with triple-negative breast cancer (TNBC) and associated with poor prognosis. Th

Externí odkaz: https://doaj.org/article/17180d15d53a444b97cb83ce78fb7480

Supplementary Methods and Materials and Supplementary Figures 1-2 from Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors

Autor: Jordan Berlin, Darrin Beaupre, Robert A. Beckman, Abdel-Baset Halim, Agnes Ang, Chi-Yuan Wu, Thore Hettmann, Catherine Copigneaux, Lorrin Yee, Vicki Keedy, Lisa Malburg, Naiyer Rizvi, Moacyr Oliveira, Pasi A. Jänne, Patricia LoRusso

PDF - 278K, Supplementary Methods and Materials, QTc prolongation results. Supplementary Figure 1 - QTc prolongation compared with serum U3-1287 concentration. Supplementary Figure 2 - U3-1287-mediated pancreatic xenograft growth inhibition)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8088012567f918b89bc000dffe8b6149
https://doi.org/10.1158/1078-0432.22451111

Futibatinib for FGFR2 -Rearranged Intrahepatic Cholangiocarcinoma

Autor: Lipika Goyal, Funda Meric-Bernstam, Antoine Hollebecque, Juan W. Valle, Chigusa Morizane, Thomas B. Karasic, Thomas A. Abrams, Junji Furuse, Robin K. Kelley, Philippe A. Cassier, Heinz-Josef Klümpen, Heung-Moon Chang, Li-Tzong Chen, Josep Tabernero, Do-Youn Oh, Amit Mahipal, Markus Moehler, Edith P. Mitchell, Yoshito Komatsu, Kunihiro Masuda, Daniel Ahn, Robert S. Epstein, Abdel-Baset Halim, Yao Fu, Tehseen Salimi, Volker Wacheck, Yaohua He, Mei Liu, Karim A. Benhadji, John A. Bridgewater

Publikováno v: New England Journal of Medicine, 388(3), 228-239. Massachussetts Medical Society
Goyal, L, Meric-Bernstam, F, Hollebecque, A, Valle, J W, Morizane, C, Karasic, T B, Abrams, T A, Furuse, J, Kelley, R K, Cassier, P A, Klümpen, H-J, Chang, H-M, Chen, L-T, Tabernero, J, Oh, D-Y, Mahipal, A, Moehler, M, Mitchell, E P, Komatsu, Y, Masuda, K, Ahn, D, Epstein, R S, Halim, A-B, Fu, Y, Salimi, T, Wacheck, V, He, Y, Liu, M, Benhadji, K A & Bridgewater, J A 2023, ' Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma ', New England Journal of Medicine, vol. 388, no. 3, pp. 228-239 . https://doi.org/10.1056/NEJMoa2206834

Background: Alterations in fibroblast growth factor receptor 2 (FGFR2) have emerged as promising drug targets for intrahepatic cholangiocarcinoma, a rare cancer with a poor prognosis. Futibatinib, a next-generation, covalently binding FGFR1-4 inhibit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0afcafd318735846a74b18ed60752c0b
https://research.vumc.nl/en/publications/cd4cc245-ebdb-4ee6-adae-ae845072be13

Not All Biomarkers Are Worthwhile

Autor: Abdel-Baset Halim

Publikováno v: Handbook of Biomarkers and Precision Medicine ISBN: 9780429202872

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3abd207e65d87a4f7de907da4b178d16
https://doi.org/10.1201/9780429202872-64

Population pharmacokinetic-pharmacodynamic modeling analysis of intrinsic FXa and bleeding from edoxaban treatment

Autor: Abdel-Baset Halim, Raymond Miller, Dongwoo Kang, SaeHeum Song

Publikováno v: The Journal of Clinical Pharmacology. 54:910-916

Edoxaban is an oral, once-daily, direct factor Xa (FXa) inhibitor that has been evaluated for the prevention of stroke in patients with atrial fibrillation (AF) and for the treatment and prevention of venous thromboembolism (VTE) recurrence. Pharmaco

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7028efebb013d487f5ae733d96cde5e
https://doi.org/10.1002/jcph.306